Last month, the company announced two transactions that it said would enable it to regain compliance with the Nasdaq's listing requirement.
An analyst said the DetermaVu test could potentially be best in class for lung cancer diagnosis and that CMS could begin reimbursing for it in late 2020.
The 360Dx Index was up 12 percent last month as shares of Accelerate Diagnostics, Veracyte, and Exact Sciences each improved more than 40 percent month over month.
The firm plans to offer more than 13 million shares of its common stock at $.225 per share. The offering will close on or about Jan. 14.
The company's diagnostics, diagnostics excluding blood, and breast health divisions are all anticipated to post healthy year-over-year improvements.
Veracyte was the only company in the 360Dx Index whose stock price rose last month while NantHealth, NeoGenomics, and Accelerate Diagnostics saw sharp declines.
The expected net proceed are now $5.4 million, down from an earlier anticipated $9.1 million. Investors reacted negatively to the news today.
The company had been warned in March that it failed to meet a listing requirement calling for a minimum $1 per share closing price of its common stock.
Seventeen of the 25 companies in the 360Dx Index saw their shares decline last month. Invitae paced the decliners, while GenMark led the gainers.
Leading the gainers in the 360 Index was GenMark, whose stock price was up 30 percent last month. Invitae led the decliners as its share price fell 24 percent.